Join us at Booth #3605

Saturday, December 3, 2016

TIME EVENT PRESENTER/S LOCATION
7:45 a.m. PT Oral Presentation (Abstract #56)
CD19 CAR T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia
Cameron J. Turtle, M.B.B.S., Ph.D.
Fred Hutchinson Cancer Research Center
San Diego Convention Center, Room 6AB
8:15 a.m. PT Oral Presentation (Abstract #58)

Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL

Mark B. Geyer, M.D.
Memorial Sloan Kettering Cancer Center
San Diego Convention Center, Room 6AB
4:30 p.m. PT Oral Presentation (Abstract #219)

CD19 CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, M.D.
Seattle Children’s Research Institute
Marriott Marquis San Diego Marina Marriott Grand Ballroom
Salons 11-13
5:30 p.m. – 7:30 p.m. Oral Presentation (Abstract #1852)
Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity by Cell Dose (Abstract #1852)
Cameron J. Turtle, M.B.B.S., Ph.D.,
Fred Hutchinson Cancer Research Center
San Diego Convention Center, Hall GH

Sunday, December 4, 2016

TIME EVENT PRESENTER/S LOCATION
6:00 p.m. – 8:00 p.m. Oral Presentation (Abstract #3231)
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Jim Qin, Senior Research Associate
Juno Therapeutics
San Diego Convention Center, Hall GH

Monday, December 5, 2016

TIME EVENT PRESENTER/S LOCATION
7:15 a.m. PT Oral presentation (Abstract #650)
Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Nirali Shah, M.D.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute

San Diego Convention Center, Room 6CF
7:30 a.m. PT Oral presentation (Abstract #651)
Creation of The First Non-Human Primate (NHP) Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T cell-mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-directed CAR T Cell Therapy
Agne Taraseviciute, M.D., Ph.D.
Seattle Children’s Research Institute
San Diego Convention Center Room 6CF
7:45 a.m. PT Oral presentation (Abstract #586)
Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR T Cell Toxicity Management
Rebecca Gardner, M.D.
Seattle Children’s Research Institute
Marriott Marquis San Diego Marina, Marriott Grand Ballroom Salons 2-4
3:45 p.m. PT Oral presentation (Abstract #1001)
EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML
Aude G. Chapuis, M.D.

Fred Hutchinson Cancer Research Center

San Diego Convention Center Room 24
6:00 –

8:00 p.m. PT

Poster presentation (Abstract #4192)
Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Jeremy S. Abramson, M.D.
Massachusetts General Hospital Cancer Center
San Diego Convention Center, Hall GH
6:00 –

8:00 p.m. PT

Poster presentation (Abstract #4712)
Identification of Small Molecule Modulators to Enhance the Therapeutic Properties of Chimeric Antigen Receptor T Cells (Abstract #4712
Jonathan Rosen, Ph.D.
Fate Therapeutics
San Diego Convention Center, Hall GH

Investor Relations:
Nicole Keith, 206-566-5521
nikki.keith@junotherapeutics.com

Media:
Christopher Williams, 206-566-5660
chris.williams@junotherapeutics.com